Gaebe Karolina, Li Alyssa Y, Das Sunit
Institute of Medical Science, Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 3K1, Canada.
Division of Neurosurgery, St. Michael's Hospital, University of Toronto, 30 Bond Street, Toronto, ON M5B 1W8, Canada.
Cancers (Basel). 2021 Nov 27;13(23):5973. doi: 10.3390/cancers13235973.
Nearly 30% of patients with cancer will develop intracranial metastatic disease (IMD), and more than half of these patients will die within a few months following their diagnosis. In light of the profound effect of IMD on survival and quality of life, there is significant interest in identifying biomarkers that could facilitate the early detection of IMD or identify patients with cancer who are at high IMD risk. In this review, we will highlight early efforts to identify biomarkers of IMD and consider avenues for future investigation.
近30%的癌症患者会发生颅内转移性疾病（IMD），其中超过一半的患者在确诊后的几个月内死亡。鉴于IMD对生存和生活质量的深远影响，人们对识别能够促进IMD早期检测或识别高IMD风险癌症患者的生物标志物有着浓厚兴趣。在这篇综述中，我们将重点介绍识别IMD生物标志物的早期努力，并探讨未来的研究途径。
